DCR STAT3
Alternative Names: DCR-STAT3; DCRSTAT3 - Dicerna PharmaceuticalsLatest Information Update: 17 Jun 2024
At a glance
- Originator Dicerna Pharmaceuticals
- Class Amides; Amino sugars; Antineoplastics; Drug conjugates; Small interfering RNA
- Mechanism of Action RNA interference; STAT3 transcription factor expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 06 Nov 2023 DCR STAT3 is available for licensing as of 06 Nov 2023. https://dicerna.com/our-company/collaborating/
- 14 Aug 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT06098651)